The VICTORIA-1 trial showed an unprecedented benefit for the gedatolisib triplet, with a hazard ratio of 0.24 in PIK3CA wild-type patients. The dramatic improvement suggests that PAM pathway activation is a dominant resistance mechanism even without a PIK3CA mutation, opening a new treatment avenue.

For the complex scenario of patients with both ESR1 and PIK3CA mutations, a combination approach shows significant promise. The AVERA trial, combining an oral SERD (gerodestrant) with an mTOR inhibitor (everolimus), addressed both pathways and demonstrated a median progression-free survival of over 10 months, suggesting a superior strategy to targeting a single mutation.

The INOVO-123 trial strategically investigates a PI3K inhibitor-based triplet therapy for endocrine-sensitive, PIK3CA-mutated breast cancer. This moves beyond its current approval in the endocrine-resistant setting, aiming to establish its efficacy for patients with de novo metastatic disease or as a first-line treatment, thereby widening its use much earlier in the patient journey.

The VICTORIA-1 trial found that gedatolisib, a pan-PI3K/mTOR inhibitor, significantly improves progression-free survival in patients with PIK3CA *wild-type* tumors after CDK4/6 inhibitor progression. This is a crucial finding for a patient group lacking clear targeted options and broadens the utility of targeting the PI3K pathway beyond just mutated tumors.

For patients with a PIK3CA mutation who relapse on or shortly after adjuvant endocrine therapy, the INAVO120 trial established a new standard of care. Adding inavolisib to palbociclib and fulvestrant significantly improved overall survival by seven months, providing a potent option for this particularly high-risk, endocrine-resistant population.

Not all mutations are equal. PIK3CA alterations are often present from the start (truncal mutations), indicating a more aggressive cancer. In contrast, ESR1 mutations are typically acquired later as a direct mechanism of resistance to endocrine therapy, making repeat testing after disease progression crucial.

The Victoria 1 study showed that adding a CDK4/6 inhibitor (triplet therapy) improved outcomes only in patients with PIK3CA wild-type tumors. In PIK3CA-mutant tumors, the doublet therapy was equally effective. This surprising finding highlights that distinct resistance mechanisms are at play and that mutation status is critical for selecting optimal combination regimens.

Three major trials (RIGHT Choice, PADMA, OMBRE) definitively show that starting with a CDK4/6 inhibitor plus endocrine therapy is superior to upfront chemotherapy for newly diagnosed, symptomatic metastatic breast cancer. This approach provides better progression-free survival without the toxicity of chemotherapy and, critically, does not result in a slower time to response.

For patients with both ESR1 and PIK3CA mutations, emerging data suggests prioritizing an oral SERD-based combination. The EMBER-3 trial showed imlunestrant plus abemaciclib achieved a ~12-month PFS in this subgroup, starkly outperforming the ~5.6-month PFS seen with PI3K/AKT inhibitor combinations like capivasertib-fulvestrant in the CAPItello-291 trial.